FIELD: medicine; pharmaceutics.
SUBSTANCE: present invention refers to medicine and pharmacy, namely to stable aqueous liquid compositions of amylin analogues. Aqueous liquid pharmaceutical composition containing an amylin analogue, which is [19CD]-isoGlu-RD()GTATK()ATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSNT-Hyp-NH2 or a pharmaceutically acceptable salt thereof; wherein the composition contains an amylin analogue in concentration of 0.4 mg/ml to 25 mg/ml and a buffer in concentration of 0.5 mM to 25 mM, where the composition has pH of 5.8 to 6.9.
EFFECT: proposed invention increases stability of aqueous compositions of amylin analogue during long-term storage, at low concentration of buffer and certain pH range.
15 cl, 12 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL PARENTERAL COMPOSITION OF DOUBLE AGONIST GLP1/2 | 2020 |
|
RU2828220C2 |
| PHARMACEUTICAL PARENTERAL COMPOSITION OF DOUBLE AGONIST GLP1/2 | 2020 |
|
RU2815643C2 |
| FORMULATIONS OF GLUCAGON-LIKE PEPTIDE-2 (GLP-2) ANALOGUES | 2019 |
|
RU2833459C2 |
| DRUG FORM FOR hGH AND rhIGF-1 COMBINATION+ | 2010 |
|
RU2558821C2 |
| LIQUID FORMULATIONS OF GLUCAGON ANALOGUES | 2021 |
|
RU2819934C1 |
| CITRATE FREE PHARMACEUTICAL COMPOSITIONS COMPRISING ANAKINRA | 2012 |
|
RU2599848C2 |
| STABLE LIQUID PHARMACEUTICAL COMPOSITION | 2018 |
|
RU2773747C2 |
| STABLE BINDING PREPARATIONS BASED ON IgG4 | 2013 |
|
RU2644214C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING PLASMINOGEN, AND USE THEREOF | 2015 |
|
RU2711989C2 |
| STABLE PHARMACEUTICAL COMPOSITION | 2017 |
|
RU2736830C2 |
